Trial Profile
A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA or Zoledronic Acid in Sweden, Denmark, and Norway
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Zoledronic acid
- Indications Cancer; Osteonecrosis
- Focus Adverse reactions
- Sponsors Amgen
- 22 Oct 2019 Status changed from active, no longer recruiting to completed.
- 28 Mar 2016 Planned number of patients changed from 3600 to 2100 as per ClinicalTrials.gov record.
- 28 Mar 2016 Planned End Date changed from 1 Dec 2019 to 1 Sep 2019 as per ClinicalTrials.gov record.